Are Borosil Scientific Ltd latest results good or bad?

1 hour ago
share
Share Via
Borosil Scientific Ltd's Q4 FY26 results are positive, showing a net profit of ₹27.21 crores and a 10.57% revenue growth year-on-year, but concerns about sustainability due to a low effective tax rate and weak return metrics remain. Overall, the company demonstrates strong operational performance but needs to improve capital efficiency.
Borosil Scientific Ltd's latest financial results for Q4 FY26 demonstrate a significant operational turnaround, highlighted by a net profit of ₹27.21 crores, which reflects a substantial year-on-year increase of 213.84%. This marks a notable recovery from the loss reported in the previous quarter, showcasing the company's ability to navigate seasonal challenges effectively.
The revenue for the quarter reached ₹143.17 crores, representing a year-on-year growth of 10.57% and an 18.03% increase compared to the previous quarter. This achievement indicates a consistent upward trajectory in sales, as it is the highest quarterly revenue recorded in at least seven quarters. The operating margin improved to 22.43%, the best in over a year, driven by disciplined cost management and operational efficiency. The profit before tax surged to ₹29.15 crores, further emphasizing the company's enhanced profitability. However, it is important to note that the reported profit was influenced by an unusually low effective tax rate of 6.52%, significantly lower than historical averages. If normalized, the profit figures would likely be lower, raising questions about the sustainability of such high profitability levels in future quarters. In terms of financial health, Borosil Scientific maintains a conservative balance sheet with minimal debt, reflected in a net debt-to-equity ratio of -0.27, indicating a net cash position. This financial strength provides the company with strategic flexibility for future investments. Despite the positive operational results, the company has seen an adjustment in its evaluation, reflecting ongoing concerns regarding its weak return on equity (ROE) of 4.53% and return on capital employed (ROCE) of 6.91%. These metrics suggest that while quarterly profitability has improved, there remains significant room for enhancement in capital efficiency and asset utilization. Overall, Borosil Scientific's Q4 FY26 results highlight a strong operational performance, yet the sustainability of this performance and the company's valuation relative to its peers warrant careful consideration moving forward.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News